Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; and.
Department of Radiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
J Nucl Med. 2021 Jun 1;62(6):765-770. doi: 10.2967/jnumed.120.243287. Epub 2021 Feb 12.
The genetic code to life is balanced on a string of DNA that is under constant metabolic and physical stress from environmental forces. Nearly all diseases have a genetic component caused by or resulting in DNA damage that alters biology to drive pathogenesis. Recent advancements in DNA repair biology have led to the development of imaging tools that target DNA damage response and repair proteins. PET has been used for early detection of oncogenic processes and monitoring of tumor response to chemotherapeutics that target the DNA repair machinery. In the field of precision medicine, imaging tools provide a unique opportunity for patient stratification by directly measuring drug target expression or monitoring therapy to identify early responders. This overview discusses the state of the art on molecular imaging of DNA damage and repair from the past 5 years, with an emphasis on poly[adenosine diphosphate ribose]polymerase-1 as an imaging target and predictive biomarker of response to therapy.
生命的遗传密码存在于 DNA 链上，而 DNA 链会不断受到环境因素引起的代谢和物理压力的影响。几乎所有的疾病都有遗传成分，这些遗传成分是由 DNA 损伤引起的，或者是由 DNA 损伤导致的生物学改变引起的，从而导致发病机制。最近 DNA 修复生物学的进展导致了成像工具的开发，这些工具针对 DNA 损伤反应和修复蛋白。正电子发射断层扫描 (PET) 已被用于早期检测致癌过程，并监测针对 DNA 修复机制的化学疗法对肿瘤的反应。在精准医疗领域，成像工具通过直接测量药物靶点的表达或监测治疗来识别早期反应者，为患者分层提供了独特的机会。本文从过去 5 年的角度讨论了 DNA 损伤和修复的分子成像的最新进展，重点介绍了聚（腺苷二磷酸核糖）聚合酶-1 作为成像靶点和预测治疗反应的生物标志物。
